Viatris Expects First Interchangeable Biosimilar Designations For Insulins In July

Firm Expecting Landmark Nods For Both Glargine And Aspart

 
• By Dean Rudge
  
FDA building.
July is a key month for Viatris' FDA insulin application • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products